a public good project by the
Synthesis
Company
of California

© 2026

S. Gail Eckhardt | doi.page

0 works0 citations0 h-index

S. Gail Eckhardt

University of Pittsburgh(US)Baylor College of Medicine(US)

Publications by Year

Research Areas

Colorectal Cancer Treatments and Studies, Cancer, Hypoxia, and Metabolism, Melanoma and MAPK Pathways, Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology

Most-Cited Works

→ Clinical Applications of Metabolomics in Oncology: A Review(2009)741 cited
→ Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer(2010)437 cited
→ Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.(1996)352 cited
→ MERTK receptor tyrosine kinase is a therapeutic target in melanoma(2013)144 cited
→ Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies(1999)133 cited
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.(2002)
→

Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells

(2009)

119 cited

→ Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc.(1994)108 cited

→ Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies(2000)85 cited

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.(2002)